Study Group: Experts for Volume Trends of Coated Stents Systems(?)
Council Members in this Study Group: 40
Request a survey with this Study Group
Leading Experts in this Study Group
Professor of Medicine
Finch University of Health Science-Chicago Medical School
Rohit Arora, MD, FACC, FAHA, FASCI, FACP, is a Professor of Medicine and Professor of Physiology and Biophysics at Chicago Medical School, Illinois. He is also the Chairman of Cardiology and Associate Chairman of Medicine in the Department of Medicine. Dr. Arora is also Chief of Cardiology at the North...
Samuel Butman, MDInterventional Cardiologist
Verde Valley Heart LLC
Samuel Butman, MD, is an Interventional Cardiologist at Verde Valley Medical Center. Dr. Butman is also a Clinical Associate Professor of Medicine at University Medical Center in Tucson, Arizona. He has also served as the Director of Cardiology Interventional Fellows Program and Director of Cardiac...
Director of Cardiac Catheterization Lab
Wadsworth VA Medical Center
Ramin Ebrahimi, MD, is Associate Clinical Professor at the University of California in Los Angeles. He is also Director of the Cardiac Catheterization Laboratory and Assistant Director of Nuclear Cardiology at the Wadsworth VA Medical Center. Dr. Ebrahimi’s clinical and research interests focus on interventional...
Division Chief of Cardiovascular Medicine
UNIVERSITY HOSPITAL - Case Medical Center
Daniel Simon, MD, is Division Chief of Cardiovascular Medicine, Director of the Heart and Vascular Institute at the University Hospitals Case Medical Center, and Herman K. Hellerstein Professor of Cardiovascular Research at the Case Western Reserve University School of Medicine. He graduated summa cum...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
The Endeavour stent appears to have a higher restenosis rate than currently marketed Drug Eluting Stents without the improved safety profile claimed by the company. This finding is at odds with the companies marketing message to cardiologists. These studies, along with the introduction of...
It is well known that the addition of thiazide diuretic to ACEI or ARB treatment adds about 10 mm Hg reduction on top of the 10 mm Hg reduction provided by the ACEI or ARB agent. It is expected that blocking renin in the renin angiotensin system with Tekturna would provide a similar result.
Questions about bleeding, proper dose and appropriate patient subsets will limit use
TRITON-TIMI 38 study of 13,608 patients with ACS compared prasugrel against clopidogrel, combined with aspirin. Prasugrel reduced the combined rate of CV death, MI or stroke (12.1% for clopidogrel vs. 9.9% for prasugrel). The benefit came at a cost of increased serious bleeding (1.4%, vs....
The reality that the actual details of the ENHANCE have not been circulated and that alternate explanations or caveats may be raised is probably unimportant. The bottom line carries the day and the bottom line is that the trial's title, ENHANCE, was not achieved by the addition of VYTORIN when...
The impact on Vytorin and zetia sales will be modest reduction after the release of ENHANCE data
Physicians have several possible conclusions that can be taken; These include: - the trial is flawed - the selection of patients with much less CIMT than previous trials such as ASAP and ARBITER flaws the study - the failure to meet the trial endpoint is only a surrogate and clinical trial data...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Medical Device Manufacturer
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Owner
- Director
- Physician - Division Head